[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201811478TA - Freeze-dried formulations of antibacterial protein - Google Patents

Freeze-dried formulations of antibacterial protein

Info

Publication number
SG11201811478TA
SG11201811478TA SG11201811478TA SG11201811478TA SG11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA
Authority
SG
Singapore
Prior art keywords
staphylococcus
international
dong
songpa
seoul
Prior art date
Application number
SG11201811478TA
Other languages
English (en)
Inventor
Seong Jun Yoon
Soo Youn Jun
Gi Mo Jung
Sang Hyeon Kang
Original Assignee
Intron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intron Biotechnology Inc filed Critical Intron Biotechnology Inc
Publication of SG11201811478TA publication Critical patent/SG11201811478TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201811478TA 2016-01-12 2017-01-09 Freeze-dried formulations of antibacterial protein SG11201811478TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277588P 2016-01-12 2016-01-12
PCT/IB2017/050091 WO2017122114A1 (fr) 2016-01-12 2017-01-09 Formulations lyophilisées de protéine antibactérienne

Publications (1)

Publication Number Publication Date
SG11201811478TA true SG11201811478TA (en) 2019-01-30

Family

ID=59310884

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811478TA SG11201811478TA (en) 2016-01-12 2017-01-09 Freeze-dried formulations of antibacterial protein

Country Status (16)

Country Link
US (2) US20190183803A1 (fr)
EP (1) EP3402466A4 (fr)
JP (1) JP7085482B2 (fr)
KR (2) KR20180114011A (fr)
CN (2) CN116831993A (fr)
AU (1) AU2017208117B2 (fr)
BR (1) BR112018014181A2 (fr)
CA (1) CA3010565C (fr)
MX (1) MX2018008544A (fr)
MY (1) MY193907A (fr)
NZ (1) NZ749843A (fr)
RU (2) RU2708393C1 (fr)
SG (1) SG11201811478TA (fr)
UA (1) UA125388C2 (fr)
WO (1) WO2017122114A1 (fr)
ZA (1) ZA201804014B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ749842A (en) * 2016-01-12 2024-11-29 Intron Biotechnology Inc An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
CN111588841A (zh) * 2019-02-21 2020-08-28 中国人民解放军军事科学院军事医学研究院 一种可气溶胶化的seb类毒素疫苗干粉吸入剂
RU2744331C1 (ru) * 2020-07-07 2021-03-05 Общество с ограниченной ответственностью "ГЕМАТЕК" Изотонический инфузионный раствор
WO2022145518A1 (fr) * 2020-12-29 2022-07-07 주식회사 바이오빛 Composition de revêtement dur comprenant une protéine antibactérienne et procédé de préparation associé

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500539A (en) * 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
EP1301601A2 (fr) * 2000-07-19 2003-04-16 PHARMACIA & UPJOHN COMPANY Sequence nucleotidique complete du gene de la proteine ribosomale de staphylococcus aureus , s16, et methodes d'identification de substances antibacteriennes
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
KR100910961B1 (ko) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
WO2009118754A2 (fr) * 2008-03-28 2009-10-01 Astron Research Limited Procédé pour préparer une composition lyophilisée stable
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
CN103003422B (zh) 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
CN102648978B (zh) 2011-04-19 2013-09-25 杭州九源基因工程有限公司 一种稳定的蛋白药物制剂及其制备方法
WO2013180316A1 (fr) * 2012-05-29 2013-12-05 주식회사 인트론바이오테크놀로지 Composition pouvant améliorer la stabilité des protéines de lysine de bactériophages

Also Published As

Publication number Publication date
JP7085482B2 (ja) 2022-06-16
AU2017208117A1 (en) 2018-07-26
KR20180114011A (ko) 2018-10-17
CA3010565C (fr) 2024-05-14
WO2017122114A1 (fr) 2017-07-20
ZA201804014B (en) 2019-04-24
MY193907A (en) 2022-10-31
CN108463215A (zh) 2018-08-28
MX2018008544A (es) 2019-05-15
JP2019501931A (ja) 2019-01-24
US20210161821A1 (en) 2021-06-03
CA3010565A1 (fr) 2017-07-20
RU2708393C1 (ru) 2019-12-06
UA125388C2 (uk) 2022-03-02
AU2017208117B2 (en) 2022-07-14
RU2019138064A3 (fr) 2020-05-29
BR112018014181A2 (pt) 2018-12-26
EP3402466A1 (fr) 2018-11-21
RU2019138064A (ru) 2019-12-06
NZ749843A (en) 2024-09-27
KR20250004941A (ko) 2025-01-08
US20190183803A1 (en) 2019-06-20
RU2734308C2 (ru) 2020-10-15
CN116831993A (zh) 2023-10-03
EP3402466A4 (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
SG11201811478TA (en) Freeze-dried formulations of antibacterial protein
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804713VA (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201803951QA (en) Oligonucleotides for inducing paternal ube3a expression
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201408174UA (en) Antibody formulation
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201407284TA (en) Polypeptide mixes with antibacterial activity
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201807075QA (en) A ball launcher and ball gaming system including such ball launcher
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201808804TA (en) A method to enhance wound healing using silk-derived protein
SG11201811479RA (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201909602TA (en) Compositions and methods involving probiotic molecules